Ann: Notice Under Section 708A, page-24

Scottsmyname, I will only clarify that IMO there will not be any phase 3 in Multiple system atrophy because MSA is an orphan disease and ATH434 has been granted an orphan status in the USA and EU. With orphan status, a drug can get to the market after positive results in phase 2. IMO, when Stamler has been talking about phase 3, he is talking about a phase 3 study for PD, even though he has not directly told so. It would be stupid to do a phase 3 study on MSA patients but very clever after the successful ape study to do a phase 3 study on PD patients. But of course, the side effects in phase 2 need to be close to the same level as in the placebo group.